Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (51-60 of 492) with videos related to

Pageof 50
Sort By:
Expert Opinion on Investigational Drugs|January 11, 2012
MDV3100 for the treatment of prostate cancerDeborah Mukherji, Carmel J Pezaro, Johann S De-Bono
Drug Discovery Today|December 27, 2011
Abiraterone acetate: redefining hormone treatment for advanced prostate cancerCarmel J Pezaro, Deborah Mukherji, Johann S De Bono
Clinical Pharmacology and Therapeutics|July 30, 2017
Application of Liquid Biopsies in Cancer Targeted TherapyS Sumanasuriya, M B Lambros, J S de Bono
British Journal of Cancer|February 19, 2009
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancerJ E Ang, D Olmos, J S de Bono
The EPMA Journal|June 29, 2012
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?Timothy A Yap, Charles Swanton, Johann S de Bono
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
Development of therapeutic combinations targeting major cancer signaling pathwaysTimothy A Yap, Aurelius Omlin, Johann S de Bono
Cancer Cell|December 8, 2009
Steroid hormone receptors in prostate cancer: a hard habit to break?Gerhardt Attard, Colin S Cooper, Johann S de Bono
HIV Clinical Trials|October 9, 2001
Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot studyJ A Vazquez, J A Hidalgo, S De Bono
Drugs|July 28, 2012
PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancerBristi Basu, Shahneen K Sandhu, Johann S de Bono
Molecular and Cellular Endocrinology|October 12, 2011
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancerAndrew Eichholz, Roberta Ferraldeschi, Gerhardt Attard, et al.
Pageof 50

Showing results (51-60 of 492) with videos related to

Sort By:
Pageof 50
Expert Opinion on Investigational Drugs|January 11, 2012
MDV3100 for the treatment of prostate cancerDeborah Mukherji, Carmel J Pezaro, Johann S De-Bono
Drug Discovery Today|December 27, 2011
Abiraterone acetate: redefining hormone treatment for advanced prostate cancerCarmel J Pezaro, Deborah Mukherji, Johann S De Bono
Clinical Pharmacology and Therapeutics|July 30, 2017
Application of Liquid Biopsies in Cancer Targeted TherapyS Sumanasuriya, M B Lambros, J S de Bono
British Journal of Cancer|February 19, 2009
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancerJ E Ang, D Olmos, J S de Bono
The EPMA Journal|June 29, 2012
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?Timothy A Yap, Charles Swanton, Johann S de Bono
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
Development of therapeutic combinations targeting major cancer signaling pathwaysTimothy A Yap, Aurelius Omlin, Johann S de Bono
Cancer Cell|December 8, 2009
Steroid hormone receptors in prostate cancer: a hard habit to break?Gerhardt Attard, Colin S Cooper, Johann S de Bono
HIV Clinical Trials|October 9, 2001
Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot studyJ A Vazquez, J A Hidalgo, S De Bono
Drugs|July 28, 2012
PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancerBristi Basu, Shahneen K Sandhu, Johann S de Bono
Molecular and Cellular Endocrinology|October 12, 2011
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancerAndrew Eichholz, Roberta Ferraldeschi, Gerhardt Attard, et al.
Pageof 50